

Untreated Controls
Avastin (5 mg/kg; i.p.; bwk x 4)
DMXAA (21 mg/kg; i.v.; bwk @ wk1 & wk4)
Avastin + DMXAA (as above)
Relative Tumour Volume
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0
10
20
30
40
50
60
70
80
Days (Relative to Day 0 of Treatment)

Fig. 1.



Untreated Controls
Avastin (5 mg/kg; i.p.; bwk x 4)
DMXAA (21 mg/kg; i.v.; bwk @ wk1 & wk4)
Avastin + DMXAA (as above)
% < 4V0
100
80
60
40
20
0
0
10
20
30
40
50
60
70
80
Days (Relative to Day 0 of Treatment)

Fig. 2.



Untreated Controls
Avastin (5 mg/kg; i.p.; bwk x 4)
DMXAA (21 mg/kg; i.v.; bwk @ wk1 & wk4)
Avastin + DMXAA (as above)
Relative Tumour Volume
4.0
3.0
2.0
1.0
0.0
0
20
40
60
80
100
120
Days (Relative to Day 0 of Treatment)

Fig. 3.



Untreated Controls
Avastin (5 mg/kg; i.p.; bwk x 4)
DMXAA (21 mg/kg; i.v.; bwk @ wk1 & wk4)
Avastin + DMXAA (as above)
% < 4V0
100
80
60
40
20
0
0
20
40
60
80
100
120
Days (Relative to Day 0 of Treatment)

Fig. 4.



Untreated Controls
Paclitaxel (5 mg/kg; i.v.; bwk @ wk1 & wk4)
Avastin (5 mg/kg; i.p.; bwk x 4)
DMXAA (21 mg/kg; i.v.; bwk @ wk1 & wk4)
Combination (as above)
Relative Tumour Volume
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0
5
10
15
20
25
30
35
40
45
50
Days (Relative to Day 0 of Treatment)

Fig. 5.



Untreated Controls
Paclitaxel (5 mg/kg; i.v.; bwk @ wk1 & wk4)
Avastin (5 mg/kg; i.p.; bwk x 4)
DMXAA (21 mg/kg; i.v.; bwk @ wk1 & wk4)
Combination (as above)
% < 4V0
100
80
60
40
20
0
0 5 10 15 20 25 30 35 40 45 50
Days (Relative to Day 0 of Treatment)

Fig. 6.